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Background: Confirming the clinical suspicion of tuberculous meningitis (TBM) has always been
problematic. Whilst smear and culture positivity are diagnostic, these tests have low sensitivity.
The polymerase chain reaction (PCR) assay has given variable results.
Aim: This study attempted to improve the diagnostic yield by: (a) increasing the cerebrospinal
fluid (CSF) volumes; (b) testing the yield from three specimens of CSF assumed to represent
lumbar, cervico-thoracic cord, and base of brain CSF samples; (c) undertaking PCR assays using
multiple primer sets; and (d) using real-time PCR.
Method: Patients suspected of having cranial or spinal meningeal tuberculosis were entered into
the study. Three aliquots of CSF were subjected to smear, culture, and conventional and real-time
PCR. Three sets of primers — IS6110, MPB64, and PT8/9 — were used. Patients were retro-
spectively classified into four categories: ‘definite TB’ (culture positive), ‘probable TB’ (clinical
and other tests suggestive of TB), ‘not TB’, and ‘uncertain diagnosis’.
Results: A total of 68 patients were studied. There were 20 patients classified as definite TB, 24
probable TB, 17 not TB, and seven uncertain diagnosis. Forty-eight of 57 (84.2%) patients tested
were HIV seropositive. The IS6110 PCR was positive in 27 patients which included 18/20 culture
positive cases, six in the probable TB group, and three in the not TB group. The MPB64 and PT8/9
primers did not increase the yield. Real-time PCR was positive in seven additional patients.
Combining the definite and probable TB, the sensitivity of all PCR assays was 70.5% (31/44) and
specificity 87.5% (21/24).
Conclusion: Targeting multiple sites of the TB genome using conventional PCR did not increase the
number of positive cases. Real-time PCR was more sensitive. However, all the current techniques
are still too insensitive to confidently exclude the diagnosis on laboratory grounds.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Current address: Department of Neurology, Inkosi Albert Luthuli Central Hospital, Private bag X03, Mayville 4058,
South Africa. Tel.: +27 31 2402359; fax: +27 31 2402358.
E-mail address: Bhigjee@ukzn.ac.za (A.I. Bhigjee).
1201-9712/$32.00 # 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2006.07.007
Diagnosis of tuberculous meningitis 349Introduction
Tuberculosis (TB) is a major cause of morbidity and mortality.
The World Health Organization has noted that the global
incidence of TB is increasing by 0.4% per annum.1 For example,
in South Africa the prevalence has increased from190/100 000
in 1980 to 339/100 000 in 2001.2 The human immunodeficiency
virus (HIV) contributes to the increased disease burden of TB.
Central nervous system TB accounts for about 5% of all
extrapulmonary TB and tuberculous meningitis (TBM) is the
most serious complication.3Without treatmentmost patients
die and any delay in treatment results in significant morbid-
ity. The mortality rates vary from 7% to 45%.4
Confirming the clinical suspicion of TBM has always been
problematic. Extraneurological clues are often not present.
Only about 45% of patients will have chest radiographic evi-
dence of past or present TB5 and only about half will have a
positive tuberculin test.6 While the typical routine cerebrosp-
inal fluid (CSF) profile is that of a lymphocyte predominant
pleocytosis, a raised protein and a low glucose, there are too
many exceptions to exclude the diagnosis of TBM on the
absence of these parameters alone. The CSF may be acellular
in as many as 3—6% of HIV negative patients and this can be as
high as 16% in HIV positive patients.4 There may be a neutro-
philic predominance in 20—25% of HIV negative patients.4 The
protein level may be normal in about 6% and the glucose level
in about25%ofHIV negativepatients.4 Thefigures are higher in
HIV positive patients. Smears of the CSF, although diagnostic,
are positive in only 5—20% of cases.4 Culture, though the gold
standard, is positive in only about 40% of cases4 and may take
up to 6 weeks to return a positive result.
A number of strategies have been attempted to improve
the laboratory diagnosis of TBM. These include techniques to
improve smear and culture positivity, biochemical tests,
antigen and antibody tests, immunocytochemical studies,
and bacterial DNA detection kits.
The CSF of most patients with TBM contains only 100—
102 organisms/ml6 yet approximately 104 organisms/ml are
required for reliable detection with Ziehl—Neelsen and aur-
amine stains.4 The detection rate in CSF smears can be
improved by taking large volumes7,8 of CSF and spinning it
at high speeds for a prolonged period (3000  g for 30 min) as
the high lipid content of theMycobacterium tuberculosis cell
wall makes it more buoyant than other bacteria.9 Diligent
and prolonged duration of microscopy increases smear posi-
tivity. For example, Thwaites et al. have reported a smear
pick-up rate of 58%with search times varying from 1 to 50 min
(median 10 min).8
Traditionally, solidmedia suchas Lowenstein—Jensen, have
been used to cultureMycobacterium tuberculosis. It may take
4—6weeks to obtain a positive culture. Newer radiometric and
non-radiometric, semi-automated and fully automated liquid
culture systems have decreased the time to a positive result to
1—3 weeks.10,11 Thwaites et al.8 obtained a culture positivity
of 71.2% (94/132) using liquid mycobacterial growth indicator
tubes and Lowenstein—Jensen medium.
To improve the laboratory diagnosis of TBM a number of
mycobacterial antigen12,13 and antibody kits14,15 have been
designed. However, all have varying degrees of sensitivity
and positivity and have not gained wide acceptance. Sumi
et al.16 have recently developed an immunocytochemical
method to detect mycobacterial antigen in CSF monocytoidcells. This test was specific (100%) and the sensitivity was
70%. Biochemical markers such as CSF adenosine deaminase
(ADA) have been found to be elevated in TBM.14,17 However,
elevated CSF ADA levels are seen in a variety of other dis-
orders such as lymphoma and sarcoidosis. An alternative
approach would be the detection of biochemical mycobac-
terial markers such as tuberculostearic acid (TBSA), which is
a structural component of mycobacteria. Using gas chroma-
tography/mass spectrometry, French et al.18 found the
detection of TBSA in the CSF to be highly specific and
sensitive. Further, the TBSA may still be detectable for weeks
after initiation of therapy. The drawback is that this test
requires expensive equipment and skilled staff.
The CSF polymerase chain reaction (PCR) assay represents
a significant advance in the diagnosis of microbial diseases
and TBM is no exception. The results of PCR studies in the CSF
have shown a 94—100% specificity but sensitivities ranging
from 75% to 100%.19—22 Variations in the PCR methodologies
have been attempted to improve the sensitivity and speci-
ficity of the test. Primers targeting regions other than the
insertional sequence IS6110 have been used. Narayanan
et al.23 used a TRC4 target, a conserved repetitive element
specific for Mycobacterium tuberculosis, and found that the
sensitivity of the PCR can be increased by using both IS6110
and TRC4 primer sets. Nested PCR is another variation to
improve the diagnostic sensitivity and specificity.24 The pau-
city ofMycobacterium tuberculosis in the CSFmay contribute
to false negative PCR tests. Immunomagnetic enrichment of
the CSF sample has led to improved sensitivity.25
Commercially available nucleic acid amplification kits
such as the Gen-Probe Amplified Direct test26 and modifica-
tion thereof,27 and PCR kits such as the Cobas Amplicor,28,29
have demonstrated sensitivities ranging from 60% to 83% and
specificity of 100%.
A recent PCR advance is the use of real-time amplification
and product detection by fluorescence using FRET (fluores-
cence resonance energy transfer) probes or SYBR green.30,31
A modification of this test is the quantitative nested real-
time PCR.32 Real-time PCR is the fastest system and holds
promise. However, to date most studies have used sputa.
A more recently developed technique is the use of myco-
bacteriophage amplification, which detects viable organisms
in specimens.33,34 The technique is simple, does not require
expensive equipment, and results are obtained within 24—
48 hours. The sensitivity of the FAST plaque TB kit ranges
from 76% to 87% and the specificity is about 95%. These
studies were on sputum samples. The role of this technique
in the diagnosis of TBM remains to be defined, but unpub-
lished data (Sturm W, personal communication) would sug-
gest that it has an unacceptably low sensitivity.
In an attempt to improve the diagnosis of TBM we pro-
spectively evaluated the clinical features, sample collection
methods, and a variety of laboratory techniques in patients
suspected to have neurotuberculosis. The study was
approved by the ethics committee of the Nelson R. Mandela
School of Medicine.
Patients, materials, and methods
Patients suspected to have neurotuberculosis (either cranial
or spinal meningitis) on clinical grounds were entered into
the study. They were retrospectively classified into four
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from the CSF (gold standard), they were regarded as ‘definite
TB’ cases. (2) If clinical, laboratory and radiological features
suggested TBM but the culture was negative, these patients
were regarded as ‘probable TB’ cases. These patients may
have had chest radiological changes of past or present pul-
monary tuberculosis, cranial CTor MRI features such as basal
or spinal meningeal enhancement, a CSF profile typically
seen in TBM, and negative results for Gram stain, India
ink, bacterial and fungal cultures, syphilis serology, and
PCR for herpes simplex I and II, herpes zoster and cytome-
galovirus. (3) If another cause was found to explain the
neurological presentation, these cases were considered to
be ‘not TB’ cases. In these cases, other tests, e.g., crypto-
coccal antigen or response to specific non-tuberculous ther-
apy (e.g., co-trimoxazole for toxoplasmosis), led to the
alternative diagnosis. (4) An ‘uncertain diagnosis’ category
was used where extensive investigations as described above
gave equivocal results. No patient was on anti-tuberculous
therapy at the time of neurological presentation.
Routine blood tests included complete blood count, ery-
throcyte sedimentation rate, urea and electrolytes, liver
function tests, HIV antibody test, and rapid plasma reagin.
Before treatment, CSF was collected in three consecutive
lots of approximately 10 ml. The first lot was considered to
represent lumbar CSF (specimen 1 = S1), the second to repre-
sent thoracic and cervical CSF (specimen 2 = S2), and the last
to represent CSF at the base of the brain (specimen 3 = S3). It
was not possible to collect exactly 10 ml in all instances (see
results). From each specimen of 10 ml of CSF, 5 ml were used
for smear and culture. The samples were spun down for 5 min
at 3000  g, which is a standard procedure. Under these
conditions it is unlikely that buoyant bacteria were lost when
the supernatant was discarded. Some organisms may be stuck
on the inside of the tubes. To take care of this problem a small
amount of buffer and albumin was added to the sediment,
vortexed and then cultured. A portion of the pellet was
smeared on a slide and viewed under a fluorescent micro-
scope after auramine staining. Fifty fields were viewed. The
rest was cultured on 7H 11 agar and in mycobacterial indi-
cator growth tubes. These specimens were cultured at 37 8C
for 6 weeks and examined weekly for growth. The remaining
5 ml of CSF from each lot of 10 ml was divided as follows:
4.5 ml was centrifuged at 3000  g for 15 min and set aside
for molecular studies. The rest was frozen at70 8C for later
use if required. The supernatant was discarded.
Different protocols for DNA extraction were used to obtain
optimum DNA purity. These included the boiling method and
the Puregene DNA isolation kit (Puregene TM, Gentra, Min-
neapolis, USA). Once extracted, the DNAwas quantified using
gel electrophoresis. The extracted DNA was aliquoted and
stored at 70 8C for future analysis.
Three regions of the Mycobacterium tuberculosis genome
were targeted. These were the IS6110 sequence, which is a
repeat sequence present in a large number ofMycobacterium
tuberculosis strains in a variable number of copies. The
MPB64 gene codes for the MPB64 protein and is a 240 bp
region (nucleotides 460—700). The third target was a 541 bp
region within the IS6110 sequence.
Three sets of primers targeting different regions of the
Mycobacterium tuberculosis genome were: IS6110R (50CC-
CCTGCGAGCGTAGGTAGGCGTCGG30), IS6110F (50CTCGTCC-AGCGCCGCTTCGG30), MPB64R (50TCCGCTGCCAGTCGT-
CTTCC30), MPB64F (50GCTTCCGCGAGTCTAGGCCA30), PT8R
(50GTGCGGATGGTCGCAGAGAT30), and PT9F (50CTCGATG-
CCCTCACGGTTGA30).
The PCR mix was made according to recommendations
listed in the Amplitaq (Applied Biosystems) handbook. Opti-
mization for each primer set, final concentration of magne-
sium, and Taq were carried out. The ideal PCR mix for all
three PCRs were primer concentrations of 10 pmol/ml and
25 pmol/ml, MgCl2 of 0.5 mM, and Taq volume of 0.25 ml in a
50-ml reaction.
Guidelines for PCR conditions were obtained from pub-
lished data and then optimized in our laboratory. The final
PCR conditions were as follows: IS6110 (forward and reverse)
— initial denaturation of double stranded DNA molecules at
94 8C for 2 min. This was followed by cycling, which included
denaturation at 94 8C for 45 s, annealing at 68 8C for 45 s, and
extension at 72 8C for 3 min. After the 40th cycle, the final
extension was performed for another 3 min at 72 8C. A cool-
ing step was then performed at 15 8C.
MPB64 (forward and reverse) — initial denaturation of
double stranded DNA molecules at 94 8C for 4 min. This
was followed by cycling, which included denaturation at
94 8C for 1 min, annealing at 60 8C for 1 min, and extension
at 72 8C for 4 min. After the 40th cycle, the final extension
was performed for another 3 min at 72 8C. A cooling step was
then performed at 15 8C.
PT8 and PT9 (forward and reverse) — initial denaturation
of double-stranded DNA molecules at 94 8C for 1.5 min. This
was followed by cycling, which included denaturation at
94 8C for 30 s, annealing at 68 8C for 50 s, and extension at
72 8C for 3 min. After the 30th cycle, the final extension was
performed for another 3 min at 72 8C. A cooling step was then
performed at 15 8C.
For PCR standardization and sensitivity detection, assays
were performed by spiking first saline and then culture and
smear negative (sterile) CSF with the H37Rv strain of Myco-
bacterium tuberculosis (source). Dilution was performed
according to the McFarland’s standards.35 The PCR conditions
were the same as for patient samples and all three sets of
primers were used.
The real-time PCR was performed using the standard
LightCycler (Roche) protocols. Briefly, the commercially
available ready-to-use hot start reaction mixture (LightCy-
cler Fast Start DNA, Roche Molecular Biochemicals) supple-
mented with 4 mM MgCl2 was used. The final concentration
was 5.5 mM MgCl2. The same IS6110 primer set as for con-
ventional PCR was used for real-time PCR. The amplification
program began with a denaturation step at 95 8C for 10 min,
followed by cycling, which included denaturation at 95 8C for
10 s, annealing at 68 8C for 10 s, and extension at 45 8C for
10 s. The instrument was then allowed to cool to 40 8C. In
each run a positive and negative control was included. The
positive control was from a patient sample known to be
positive. The negative control contained all the reagents
except DNA, which was replaced with PCR-grade distilled
water.
The molecular researcher (RP) was blinded to the cul-
ture and clinical findings. The clinicians (HP, SM) were
blinded to the molecular results at the time of category
allocations of definite and probable TB, not TB, and uncer-
tain diagnosis.
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ity and specificity of PCR for specimens 1—3. SAS version 9
was used for analysis.
Results
Patient data
A total of 68 patients were studied. There were 28 men and
40 women. Forty-eight of 57 (84.2%) patients tested were
seropositive for HIV. The HIV status was unknown in 11. In
the definite TB category (culture positive) there were 20
patients. In the probable TB category there were 24
patients. In the not TB category there were 17 patients.
In this category there were three patients who were PCR
positive. One had cryptococcal meningitis and another
had presumed toxoplasmosis. In neither could a dual infec-
tion with TB be excluded. The third patient, who was
HIV positive, presented with seizures for which no other
cause was found. Her CSF showed a mild pleocytosis and
normal biochemistry. There were seven patients in the
uncertain diagnosis category where no other cause was
found.
The chest radiographic (CXR) and routine CSF findings
are summarized in Table 1. The CXR, lymphocyte, poly-
morph, and glucose ratio were significantly different in
the combined definite and probable categories when
compared with the not TB and uncertain diagnosis cate-
gories.
Smear results
No mycobacteria were seen on any smear.Table 1 Comparison of the definite TB and probable TB categories
Definite/p
Age (mean  SD) 32.2 (10
Sex, (%) male 20/44 (45.
HIV, n (%) positive 31/36 (86.








Grade 2 28 (63.6%)
Grade 3 5 (11.4%)
Lymphocytes (mean  SD) 68 (157)
Polymorphs (mean  SD) 155 (335
CSF/blood glucose mmol/l (mean  SD) 0.39 (0.2
CSF protein (g/l) (mean  SD) 3.67 (10
SD, standard deviation; CXR, chest radiograph. Cranial = intracranial pre
inal.
Statistical tests used: age, polymorphs, and glucose compared using the
HIV, and CXR compared using Chi-square tests.Culture results
Three lots of CSF assumed to reflect lumbar (specimen 1),
cervico-thoracic (specimen 2), and base of brain (specimen
3) samples were cultured (Table 2). Seventeen of 20 speci-
men 1 samples (85.0%) with definite TB were positive. In
three patients there was insufficient CSF for specimens 2 and
3. For specimen 2, 16/17 (94.1%) patients with definite TB
were culture positive and for specimen 3, 12/17 (70.6%) with
definite TB were positive. A further specimen 3 was con-
taminated and excluded from analysis but included in the
denominator.
Conventional PCR
Using the IS6110 primer pair, 27 patient samples were posi-
tive on conventional PCR in any specimen. These included the
18/20 culture positive cases (any specimen), six in the
probable category, and three in the not TB group. The same
results were obtained with the MPB64 primer sets. The PT8
and PT9 primer pair was positive in only nine patients, all
belonging to the definite category. Combining and using the
definite and probable TB as the gold standard, the sensitivity
was 54.5% (24/44) and the specificity was 87.5% (21/24).
Three additional patients who had other diagnoses had posi-
tive conventional and real-time PCR (see above). Since dual
infections are possible, including these three patients
increased the sensitivity to 61.4% (27/44).
Real-time PCR
Real-time PCR was positive in seven additional patients in
whom the conventional PCR was negative. All these patients
were in the probable category. Combining and using theagainst patients in the uncertain (uncert) and not TB categories
robable Uncert/not TB p Value
.0) 30.8 (8.7) 0.6
4%) 8/24 (33.3%) 0.3
1%) 17/21 (81.0%) 0.6









) 10 (16) 0.03
1) 0.54 (0.18) 0.008
.2) 1.09 (1.96) 0.0002
sentation; spinal = spinal presentation; combination = cranial + sp-
t-test; lymphocytes, CSF, and protein using the rank sum test; sex,
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Specimen 1 20 17 (85.0%) 18 (90.0%) 18 (90.0%)
Specimen 2 17 16 (94.1%) 16 (94.1%) 16 (94.1%)
Specimen 3 17 12 (70.6%) 16 (94.1%) 16 (94.1%)
Probable TB
Specimen 1 24 0 (0%) 6 (25.0%) 13 (54.2%)
Specimen 2 24 0 (0%) 6 (25.0%) 13 (54.2%)
Specimen 3 24 0 (0%) 6 (25.0%) 13 (54.2%)
Uncertain diagnosis
Specimen 1 7 0 (0%) 0 (0%) 0 (0%)
Specimen 2 7 0 (0%) 0 (0%) 0 (0%)
Specimen 3 7 0 (0%) 0 (0%) 0 (0%)
Not TB
Specimen 1 17 0 (0%) 3 (17.6%) 3 (17.6%)
Specimen 2 17 0 (0%) 3 (17.6%) 3 (17.6%)
Specimen 3 17 0 (0%) 3 (17.6%) 3 (17.6%)definite and probable TB as a gold standard, the sensitivity
was 70.5% (31/44) whilst the specificity was 87.5% (21/24).
Site of sample and comparison of culture,
conventional PCR, and real-time PCR
The results of the definite and probable categories are
summarized in Table 3. In these two categories the percent
positive on culture decreased from 38.6% at specimen 1 to
29.3% at specimen 3. The difference was not statistically
significant. On conventional and real-time PCR there was no
significant difference between specimen 1 versus specimen 2
and specimen 1 versus specimen 3.
Discussion
Various attempts have been made to improve the diagnosis of
TBM using clinical and routine laboratory criteria.36,37 These
have included duration of illness, presence of focal signs,Table 3 Comparison between culture, conventional PCR (C-PCR),
the definite TB and probable TB categories (n = 44)
Culture C-PCR
n Pos. % n
Specimen 1 44 17 38.6 44
Specimen 2 41 16 39.0 41
Specimen 3 41 12 29.3 41
Any specimen 44 20 45.5 44
Total (95% CI) 126 45 35.7
(27.3—44.7)
126
For each specimen, the real-time PCR was significantly more likely to be
p < 0.01, respectively).history of exposure, total peripheral white cell count, extent
and type of CSF pleocytosis, and CSF glucose level. Depending
on combinations of criteria, diagnostic sensitivities have
varied from 55% to 98% and specificities from 44% to 98%.
These wide ranges point to the limitations of the use of these
criteria in the individual patient. There are many exceptions
and despite a high index of suspicion in endemic areas, cases
are still missed with fatal consequences.
The HIV epidemic complicates the picture further. The
typical CT or MRI findings of basal enhancement are less
common38 and extrameningeal disease is more common.39
The CSF is more frequently acellular and may have a normal
protein or glucose level.4,39 It may be impossible to differ-
entiate TBM from cryptococcal meningitis on clinical and
routine CSF findings. The majority (48/57; 84.2%) of our
patients were HIV seropositive. Atypical features were com-
mon.
Extraneurological evidence of TB may be of some value. In
our study 32/36 (88.9%) patients with either definite or
probable TB had an abnormal chest radiograph. This figureand real-time PCR (RT-PCR) according to the specimens 1—3 in
RT-PCR
Pos. % n Pos. %
24 54.5 44 31 70.4
22 53.6 41 29 70.7
22 53.6 41 29 70.7





positive than either the conventional PCR or culture (p < 0.01 and
Diagnosis of tuberculous meningitis 353is similar to that reported by others.4 The serum sodium level
was low in 17/44 (38.6%) patients with definite and probable
TB.
The CSF pleocytosis and the CSF/plasma glucose ratio
were significantly abnormal in the definite and probable
TB categories compared to the other categories (Table 1).
The results of the smears (none positive) were disappoint-
ing despite collecting large volumes of CSF and adhering to
correct preparation of samples. Using an estimate of 5—20%
smear positivity4 we would have expected 1—4 of the 20
culture positive cases to be smear positive. Furthermore
daily positive and negative controls for auramine staining
were set up. To account for focus shift with fluorescent
microscopy a quality control slide is read first. In the past
we have checked scanty positive auramine slides with Ziehl-
Neelsen overlay and have not found it to be better (LR,
personal observation). After auramine staining 50 fields were
examined. This is equivalent to about 100 oil immersion
fields. Although none of the patients were on anti-tubercu-
lous therapy at the time of the neurological presentation,
many had evidence of previous pulmonary TB and would have
been on treatment then. This may be a possible explanation
for our negative results. These findings differ from those of
Thwaites et al.8 who saw the organisms in 58% of the cases
and in more than half within 15 min.
Culture was positive in 20/44 (45.5%) of patients (definite
and probable TB). This figure is disappointingly lower than
that 71% reported by Thwaites et al.,8 more so since that
study found that the organism could be isolated from much
smaller volumes of CSF if the patients were HIV seropositive.
A drawback of our study is that we were not able to follow up
patients to assess response to treatment as confirmatory
evidence of TB. It is possible that some of our patients in
the probable TB group may not have had TB. If one excludes
the PCR negative patients in the probable group then the
culture positivity rate increases to 58.8% (20/34). The cul-
ture yields from specimens 1—3 were 85%, 94%, and 70%,
respectively. Although the numbers are small we did not find
an increased yield in the last sample, the one that we
assumed to reflect the CSF from the base of brain.
The advent of the PCR technique held promise in the
confirmation of the diagnosis of TBM. A recent meta-analysis
of PCR40 found a high specificity (0.98) but an estimated
sensitivity of only 0.56. This meta-analysis examined single
amplification sites and reviewed studies using standard PCR
tests. There have been few studies attempting to amplify
more than one target region of the Mycobacterium tubercu-
losis genome in the same CSF sample.23 We attempted to
detect the IS6110, MPB64 and the PT8 and PT9 target regions.
We found that adding a second and a third target did not
improve the diagnostic yield. The PT8 and PT9 site was
singularly disappointing.
Real-time PCR combines rapid cycle DNA amplificationwith
fluorimetry. It eliminates the need to perform amplification
and product analysis separately.30,31 In culture samples it has
100% specificity and can detect as few as 10 organisms.
Broccolo et al.41 were able to confirm the TBM diagnosis in
14 samples of which only three were culture positive. We
targeted the IS6110 region and compared conventional PCR
with real-time PCRusing the LightCycler instrument. The pick-
up rate was consistently higher with real-time PCR. No con-
ventional PCR positive result was negative with real-time.The lower specificity of both conventional (87%) and real-
time (87.5%) PCR in our study differs from the 98% obtained in
the meta-analysis.40 This might reflect the fact that some of
our cases selected as probable TB may not have had TB.
The paucity of organisms is well established and is usually
in the range of 100—102/ml of CSF.6 The highest concentra-
tions of mycobacteria are thought to be at the base of the
brain. To test this finding we collected CSF in three lots of
approximately 10 ml each on the assumption that the last lot
would represent a CSF sample from the base of the brain and
have highest concentration of organisms. However, we found
no difference in the sampling sites using culture, conven-
tional PCR, and real-time PCR.
Conclusion
This study highlights, once again, the difficulty in confirming
the diagnosis of TBM. Whilst the routine cellular and bio-
chemical CSF findings may be suggestive, they are not very
specific. Priority should be given to improving smear and
culture techniques. Despite the use of auramine staining,
where 50 fields are equivalent to 100 oil immersion fields, no
smears were positive. This is in contrast to another study8
where the pick-up rate was over 50%.
Real-time PCR represents an advance over conventional
PCR. All seven additional cases were in the probable TB
group, thus improving the PCR sensitivity from 55.8% in
the conventional PCR to 72.1% in the real-time PCR. Nested
real-time PCR may further improve the sensitivity.32 This
approach needs to be explored in greater depth.
Future studies should evaluate techniques to detect a
specific immune response in the CSF42 or to detect specific
mycobacterial proteins.43 The former, however, may have
limited success due to paucity of cells in the CSF, whilst the
latter requires expensive equipment.
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